Genomic Health
Genomic Health was a company focusing on genetic research specifically in cancer detection, based out of Redwood City, California.[2] The company was acquired by and merged with Exact Sciences Corporation in 2019.
Company logo | |
| Company type | Subsidiary |
|---|---|
| Industry | Genomics |
| Founded | August 2000 in Redwood City, California, U.S. |
| Founder | Randy Scott |
| Defunct | 2019 (Acquired by Exact Sciences) |
| Successor | Exact Sciences Corporation |
| Headquarters | Redwood City, California, U.S. |
Key people |
|
| Products | Oncotype DX |
Number of employees | 863 (2017) |
| Website | www |
| Footnotes / references [1][2][3] | |
History edit
Genomic Health, Inc. was founded in 2000 by Randy Scott, who had previously founded and been CEO at Incyte.[4] He formed the company after a close friend was diagnosed with cancer and had the idea for treatment based on the specific genome of their tumor.[5]
By 2003 Genomic Health had developed Oncotype DX, a genomic assay that quantified the likelihood of breast cancer recurrence.[6] This development took the company over three years and US$30,000,000 to complete and then had to convince skeptics at the time of the validity of genetic testing.[6]
In July 2005 Genomic Health filed for an initial public offering to sell up to US$75,000,000 in common stock. Investors at the time already included Versant Ventures and Kleiner Perkins Caufield & Byers.[7] On September 29, 2005 it was listed on the NASDAQ with the symbol GHDX with the initial share price of US$12 for 5016722 shares.[8]
Genomic Health also started a subsidiary in 2010, Invitae, with the goal of aggregating multiple genetics tests. Invitae was spun off in 2012.[9]
The company expanded with international headquarters in Geneva Switzerland and UK headquarters in London in 2011.[10]
In July 2019, Exact Sciences announced that it was purchasing Genomic Health to increase the variety of medical tests they offer.[11]
See also edit
References edit
- ^ "US SEC: Form 10-K Genomic Health, Inc". U.S. Securities and Exchange Commission. Retrieved April 3, 2018.
- ^ a b "GENOMIC HEALTH, INC". OpenCorporates. 13 December 2016. Retrieved 10 January 2017.
- ^ Chaykowsk, Kathleen (10 April 2012). "CEO's dedication is behind Genomic Health's cancer tests". Peninsula Press. Retrieved 10 January 2017.
- ^ Susan McKinnon; Sydel Silverman (1 June 2005). Complexities: Beyond Nature and Nurture. University of Chicago Press. p. 239. ISBN 978-0-226-50024-9. Retrieved 10 January 2017.
- ^ Cook, Kevin (7 October 2013). "Genomic Health Has Sickly Stock Chart". Forbes. Retrieved 10 January 2017.
- ^ a b Chess, Robert; Denend, Lyn; Zenios, Stefanos (2006). "Genomic Health: Launching a Paradigm Shift ... and an Innovative New Test". Stanford Graduate School of Business. Retrieved 10 January 2017.
- ^ Simmers, Tim (19 July 2005). "Genomic Health files for an IPO". East Bay Times. Retrieved 10 January 2017.
- ^ "GENOMIC HEALTH INC (GHDX) IPO". NASDAQ. Retrieved 10 January 2017.
- ^ Lash, Alex (20 October 2015). "What's Your DNA Worth? The Scramble To Cash In On the Genome". exome. Retrieved 10 January 2017.
- ^ "Company Timeline & Milestones". Genomic Health. Retrieved 10 January 2017.
- ^ Flanagan, Cristin; Ahmed, Nabila (29 July 2019). "Exact Sciences to Buy Genomic Health for About $2.8 Billion". Bloomberg News. Retrieved 30 July 2019.
External links edit
- Official website
- Business data for Genomic Health, Inc.:
- Bloomberg
- SEC filings
- Yahoo!